Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Déjà vu.

Created on 17 Sep 2026

Authors

Aashish Omprakash Agrawal, Aditi Sanjiv Patankar, Rohini Samant

Published in

BMJ case reports. Volume 19. Issue 9. Sep 16, 2026. Epub Sep 16, 2026.

Abstract

Eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES) share overlapping clinical features, making early distinction difficult, especially in antineutrophil cytoplasmic antibody (ANCA)-negative disease where eosinophil-mediated injury may precede vasculitis. We report a male patient in his mid-20s who initially presented with fever, purpuric rash, neuropathy, marked eosinophilia, hepatic dysfunction and extensive multisystem thrombosis. Biopsy revealed eosinophilic infiltration without vasculitis, supporting a diagnosis of HES. He achieved remission on corticosteroids and anticoagulation but relapsed 5 years later with recurrent thrombosis, purpura, eosinophilia and biopsy-proven eosinophilic vasculitis, prompting reclassification as ANCA-negative EGPA. Treatment with corticosteroids, rituximab and anticoagulation resulted in sustained remission over 36 months. This case highlights the diagnostic continuum between HES and EGPA and the need for long-term follow-up with reassessment of diagnosis. Early recognition of evolving vasculitis is essential to guide appropriate immunosuppressive therapy.

PMID:
42749346
Bibliographic data and abstract were imported from PubMed on 17 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 65
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement